CD34+ cell dose predicts costs after autologous peripheral blood stem cell transplantation for breast cancer.

Adult; Antigens, CD34/analysis; Antineoplastic Combined Chemotherapy Protocols/economics/therapeutic use; Breast Neoplasms/drug therapy/economics/surgery; Cell Count; Combined Modality Therapy/economics; Costs and Cost Analysis; Drug Costs; Fees and Charges; Female; Hospital Costs; Humans; Middle Aged; Peripheral Blood Stem Cell Transplantation/economics; Transplantation, Autologous/economics

Abstract :

[en] We assessed the effect of CD34+ cell dose on costs in breast cancer patients undergoing autologous peripheral blood stem cell (PBSC) transplantation. Mean hospitalization costs were 26,992.9+/-9582.9 for patients receiving a CD34+ cell dose <5 x 10(6) cells/kg versus 22,339.4+/- 5471.1 for those receiving >5 x 10(6) CD34+ cells/kg (p=0.0065).

Disciplines :

Hematology

Author, co-author :

Baron, Frédéric ; Centre Hospitalier Universitaire de Liège - CHU > Hématologie clinique

Copizza, Sandra

Baudoux, Etienne ; Centre Hospitalier Universitaire de Liège - CHU > Thérapie cellulaire

Jerusalem, Guy ; Centre Hospitalier Universitaire de Liège - CHU > Oncologie médicale

Fillet, Georges ; Centre Hospitalier Universitaire de Liège - CHU > Hématologie clinique

Beguin, Yves ; Centre Hospitalier Universitaire de Liège - CHU > Hématologie clinique

Language :

English

Title :

CD34+ cell dose predicts costs after autologous peripheral blood stem cell transplantation for breast cancer.

Publication date :

2004

Journal title :

Haematologica

ISSN :

0390-6078

eISSN :

1592-8721

Publisher :

Ferrata Storti Foundation, Pavia, Italy

Volume :

Issue :

Pages :

1146-8

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 16 February 2009

Statistics

Number of views

83 (9 by ULiège)

Number of downloads

3 (0 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenAlex citations

Bibliography

Pedrazzoli P, Siena S. Clinical results in 2001 show high dose therapy and hematopoietic progenitor cell transplantation as a therapeutic option for breast cancer. Haematologica 2001;86:900-7.
Dazzi C, Cariello A, Rosti G, Tienghi A, Molino A, Sabbatini R, et al. Neoadjuvant high dose chemotherapy plus peripheral blood progenitor cells in inflammatory breast cancer: a multicenter phase II pilot study. Haematologica 2001;86:523-9.
Nieto Y. The verdict is not in yet. Analysis of the randomized trials of high-dose chemotherapy for breast cancer. Haematologica 2003;88:201-11.
Andre M, Baudoux E, Bron D, Canon JL, D'Hondt V, Fassotte MF, et al. Phase III randomized study comparing 5 or 10 μg per kg per day of filgrastim for mobilization of peripheral blood progenitor cells with chemotherapy, followed by intensification and autologous transplantation in patients with nonmyeloid malignancies. Transfusion 2003;43:50-7.
Schulman KA, Birch R, Zhen B, Pania N, Weaver CH. Effect of CD34( +) cell dose on resource utilization in patients after high-dose chemotherapy with peripheral-blood stem-cell support. J Clin Oncol 1999; 17:1227.
Limat S, Woronoff-Lemsi MC, Milpied N, Chartrin I, Ifrah N, Deconinck E, et al. Effect of cell determinant (CD)34+ cell dose on the cost and consequences of peripheral blood stem cell transplantation for non-Hodgkin's lymphoma patients in front-line therapy. Eur J Cancer 2000;36:2360-7.
Sautois B, Fraipont V, Baudoux E, Fassotte MF, Hermanne JP, Jerusalem G, et al. Peripheral blood progenitor cell collections in cancer patients: analysis of factors affecting the yields. Haematologica 1999;84:342-9.
Baron F, Siquet J, Schaaf-Lafontaine N, Baudoux E, Hermanne JP, Fillet G, et al. Pre-emptive immunotherapy with CD8-depleted donor lymphocytes after CD34-selected allogeneic peripheral blood stem cell transplantation. Haematologica 2002;87:78-88.
Stockerl-Goldstein KE, Reddy SA, Horning SF, Blume KG, Chao NF, Hu WW, et al. Favorable treatment outcome in non-Hodgkin's lymphoma patients with "poor" mobilization of peripheral blood progenitor cells. Biol Blood Marrow Transplant 2000;6:506-12.
Vicent MG, Madero L, Chamorro L, Madero R, Diaz MA. Comparative cost analysis of autologous peripheral blood progenitor cell and bone marrow transplantation in pediatric patients with malignancies. Haematologica 2001;86:1087-94.